Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eledon Pharmaceuticals, Inc. on March 15, 2021. The report discloses the appointment of a new Chief Financial Officer effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Paul Little as Chief Financial Officer (CFO) and principal financial officer, replacing Jon Kuwahara in that specific role. Mr. Kuwahara will continue to serve as Senior Vice President of Finance and Administration and principal accounting officer.
Management Commentary and Compensation Details
Mr. Little brings over 30 years of experience, most recently as CFO of Sientra, Inc. His employment agreement includes the following terms:
- Base Salary: $410,000 annually.
- Target Bonus: 40% of base salary.
- Equity Grant: Option to purchase 160,000 shares of Common Stock, vesting over four years. This was granted as an "inducement" award outside of standard stockholder-approved plans.
- Severance (Termination without cause/Good reason): Nine months of base salary, nine months of accelerated equity vesting, and up to nine months of COBRA health insurance reimbursement.
- Change in Control Severance: 1.0 times annual base salary, target bonus, prorated bonus, full acceleration of equity vesting, and up to 12 months of COBRA reimbursement.
The Company may also be required to indemnify Mr. Little for legal expenses and judgments arising from his service as an officer.
Investor Verification Checklist
- Verify the impact of the new CFO's appointment on the company's financial strategy and investor relations.
- Confirm the total dilution impact of the 160,000 share option grant granted outside standard equity plans.
- Review the specific definitions of "cause" and "good reason" in the employment agreement to understand severance triggers.
- Monitor future filings for the transition of duties between Mr. Little and Mr. Kuwahara.